Post-Hemorrhagic Anemia Treatment Market Share

North America Market Forecast

The North America post-hemorrhagic anemia treatment market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2036. The growth of the market in the region can be attributed majorly to the high number of hospital admissions, and the rising government focus to improve healthcare infrastructure in the region. Moreover, the market growth in North America is also credited to the rising number of people suffering from sickle cell anemia. In many severe cases, post-hemorrhagic anemia treatment is continued along the specific sickle cell disease drugs. Approximately 100,000 Americans are afflicted by sickle cell diseases. In addition to this, about 1 in every 365 Black or African-American babies is affected by SCD. Furthermore, the region’s market growth is attributed to high healthcare spending, and availability of well-established medical facilities in the region. According to the Centers for Medicare and Medicaid Services, U.S. health care spending reached USD 3.8 trillion or USD 11,582 per person in 2019. As a share of the nation's Gross Domestic Product, health spending accounted for 17.7 percent that year. In addition, strong footprint of major market players is also predicted to propel the market growth in the region in the coming years.

Asia-Pacific Market Forecast

The Asia-Pacific post-hemorrhagic anemia treatment market, amongst the market in all the other regions, is projected to hold the notable market share by the end of 2036. The growth of the market in the region can be majorly credited to rising cases of traffic accident and growing count of heart patient. As per the annual report from Ministry of Road Transport & Highways on road accidents in India 2021, there were 412,432 instances of road accidents in 2021, which resulted in 153,972 fatalities and 384,448 severe injuries. Furthermore, in Japan, the overall number of heart-related deaths reached about 206 thousand cases in 2020.